Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2012

View Archived Issues

Roche presents novel antibodies targeting human chemokine CXCR5 receptor

Multiple-assay test shows promise to diagnose depression

Phase I trials assess Listeria-based vaccines in patients with cancer

Merck KGaA patents new P70S6K inhibitors

Novel tyrosine-protein kinase JAK inhibitors prepared by Rigel Pharmaceuticals

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized

Line extension for Zyprexa approved in Japan

UCB begins phase III Cimzia trial

Merck & Co. patents novel beta3-adrenoceptor agonists

Enanta out-licenses EDP-239 development

Washburn Therapeutics patents new wound-healing antibodies

New signaling pathway inhibitors developed in Sweden

New nanopore DNA strand sequencer is the size of a USB stick

NICE recommends earlier use of tocilizumab in RA

NICE confirms guidance on prolonged-release exenatide for type 2 diabetes

Enrollment begins in phase I/II trial of PET imaging agent

BMS gains additional indication approvals for two anticancer drugs

Mechanism and activity of ladarixin sodium explored

FDA advisory committee recommends approval of obesity therapy

Daiichi Sankyo and Terumo enter new vaccine collaboration

Onyx Pharmaceuticals reaches target enrollment in ASPIRE trial

Auxilium grants Actelion exclusive rights to Xiaflex in certain territories

FDA grants first approval for drug-eluting coronary stent use in AMI

NDS for insomnia therapy accepted for review by Health Canada

Collegium Pharmaceutical gives update on COL-003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...